Sarepta Therapeutics Inc. Watch

from 8-K 36 pages 6,172,840 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Underwriting Agreement

from 8-K 35 pages 2,604,167 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 35 pages 3,817,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 51 pages Sarepta Therapeutics, Inc. 1.500% Convertible Senior Notes Due 2024 Purchase Agreement

from 8-K 34 pages 7,650,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 49 pages 5,020,921 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 46 pages 2,102,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 48 pages 3,250,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 48 pages 2,650,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) Equity Underwriting Agreement

from 8-K 36 pages Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value Per Share) At-The-Market Equity Offering Sales Agreement

from 8-K 42 pages 4,950,495 Shares of Common Stock Par Value $0.0001 742,574 Over-Allotment Shares Sarepta Therapeutics, Inc. Underwriting Agreement

from 8-K 41 pages 20,000,000 Shares of Common Stock Par Value $0.0001 3,000,000 Over-Allotment Shares Avi Biopharma, Inc. Underwriting Agreement

from SC 13D/A 10 pages Exhibit 1 Settlement Agreement

from 8-K 37 pages Avi Biopharma, Inc. Underwriting Agreement

from 8-K 16 pages Confidential

from 8-K 49 pages Avi Biopharma, Inc. 10,696,616 Shares Common Stock ($0.0001 Par Value) and Warrants to Purchase 5,348,308 Shares of Common Stock Placement Agency Agreement

from 8-K ~5 pages The Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms and Conditions Pursuant to Which Rodman & Renshaw, LLC. (“R&R”) Shall Introduce Avi Biopharma, Inc. (The “Company”) to One or More Investors in Connection With the Proposed Offering (The “Offering”) of Securities (The “Securities”) of the Company. the Gross Proceeds From the Offering Will Be Up to $27,000,000. the Terms of Such Offering and the Securities Shall Be Mutually Agreed Upon by the Company and the Investor(s). R&R’S Engagement Under This Agreement Shall Be Exclusive Until the Earlier of (I) the Completion of the Offering or (II) December 31, 2005. the Identities of the Investors to Which R&R Introduces the Company Shall Be Proprietary Information of R&R and Shall Not Be Divulged to Third Parties by the Company, Nor Used by the Company Outside the Scope of R&R’S Engagement as Described Herein

from SC 13G/A 1 page Exhibit 1 Joint Filing Agreement This Will Confirm the Agreement by and Among the Undersigned That the Schedule 13g/a Filed With the Securities and Exchange Commission on or About the Date Hereof With Respect to the Beneficial Ownership by the Undersigned of the Common Stock of Avi Biopharma, Inc. Is Being Filed, and All Amendments Thereto Will Be Filed, on Behalf of Each of the Persons and Entities Named Below in Accordance With Rule 13d-1(k) Under the Securities Exchange Act of 1934, as Amended. This Agreement May Be Executed in Two or More Counterparts, Each of Which Shall Be Deemed an Original, but All of Which Together Shall Constitute One and the Same Instrument. Dated: February 11, 2005 Smithfield Fiduciary LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge International LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge Capital Corporation By: /S/ Howard Feitelberg Howard Feitelberg, Controller Highbridge Capital Management, LLC By: /S/ Ronald S. Resnick Ronald S. Resnick, Managing Partner /S/ Glenn Dubin - Glenn Dubin /S/ Henry Swieca - Henry Swieca

from SC 13G 1 page Exhibit 1 Joint Filing Agreement

from SC 13G 1 page Exhibit 1 Schedule 13g Joint Filing Agreement